{"id":"W4319066709","doi":"10.1016/j.eclinm.2023.101826","title":"Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study","year":2023,"lang":"en","type":"article","venue":"EClinicalMedicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research; Innovaderm (Canada)","funders":"Kiniksa Pharmaceuticals","keywords":"Prurigo nodularis; Medicine; Atopy; Dermatology; Population; Placebo; Atopic dermatitis; Dupilumab; Internal medicine; Immunopathology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002540193,0.001563879,0.003529414,0.0005201857,0.0004202392,0.001375101,0.001145655,0.002734833,0.005665316],"category_scores_gemma":[0.001966243,0.0009434256,0.001875631,0.0003710618,0.001205221,0.001132834,0.0003989753,0.002448034,0.001275074],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005704783,"about_ca_system_score_gemma":0.001122205,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005116342,"about_ca_topic_score_gemma":0.0009764954,"domain_scores_codex":[0.9991731,0.0004016492,0.00005933672,0.0001506827,0.0000810542,0.0001342146],"domain_scores_gemma":[0.9987683,0.0003001777,0.0002381432,0.00008735419,0.0001090175,0.000497014],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9621984,0.01469347,0.0004373551,0.000819094,0.0004401596,0.00005847559,0.00005596919,0.00021008,0.008510519,0.00006486296,0.0004996655,0.01201208],"study_design_scores_gemma":[0.8708487,0.1264546,0.001463831,0.00002698355,0.0001744684,0.00004651445,0.00001240053,0.0001550368,0.0003358935,0.00006283431,0.0004079958,0.00001061567],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.985501,0.005345301,0.0007372642,0.000510037,0.0004631116,0.004825889,0.0009240709,0.0001343544,0.001559032],"genre_scores_gemma":[0.9857594,0.002931703,0.001221969,0.001016028,0.0005183251,0.004703869,0.0009473771,0.0000247755,0.002876511],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005665316,"threshold_uncertainty_score":0.01895231,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05024678208822447,"score_gpt":0.4160109102661748,"score_spread":0.3657641281779503,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}